The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone Release by Growth Hormone- and Prolactin-Secreting Pituitary Adenomasin Vitro-Reference-Cited by-同舟云学术

The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone Release by Growth Hormone- and Prolactin-Secreting Pituitary Adenomasin Vitro

Published:2004-04 Issue:4 Volume:89 Page:1577-1585
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:The Journal of Clinical Endocrinology & Metabolism

Author:

Hofland Leo J.,van der Hoek Joost,van Koetsveld Peter M.,de Herder Wouter W.,Waaijers Marlijn,Sprij-Mooij Diana,Bruns Christian,Weckbecker Gisbert,Feelders Richard,van der Lely Aart-Jan,Beckers Albert,Lamberts Steven W. J.

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current role of pasireotide in the treatment of acromegaly;Best Practice & Research Clinical Endocrinology & Metabolism;2024-07

2. Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess;Best Practice & Research Clinical Endocrinology & Metabolism;2024-07

3. Treatment of acromegaly with oral octreotide;Best Practice & Research Clinical Endocrinology & Metabolism;2024-07

4. A novel somatostatin receptor ligand for human ACTH – and GH –secreting pituitary adenomas;European Journal of Endocrinology;2023-12-20

5. Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors;Reviews in Endocrine and Metabolic Disorders;2023-12-05